pp-035 Tablets
Dossier type
CTD
Dossier status
Under development
Country of origin
South Korea
Comments
For Alzheimer’s disease and tauopathies (targeting pathological τ accumulation) treatment, in Phase 1. Oral small-molecule inhibitor of tau aggregation; selectively binds pathological tau, reduces tau hyperphosphorylation and aggregation, improves memory/recognition in transgenic mouse models. One of the first small-molecule tau-aggregation inhibitors in the clinic, addressing an unmet need in Alzheimer’s/tauopathies therapy.
Manufacturer #1228
A leading South Korean pharmaceutical group engaged in developing, manufacturing, and marketing prescription drugs and biologics. It operates GMP-certified facilities, maintains strong R&D capabilities, and exports therapeutic products to global markets.
Manufacturer usually replies in 5 days